ePrivacy and GPDR Cookie Consent by TermsFeed Generator
Apply to the Genome Assembly Grant for a Chance to Receive a Free Kit |Apply Now

Poster highlights research on clinically actionable gene fusions using Arima Hi-C technology

SAN DIEGO, Calif. (April 5, 2022) Arima Genomics, the leader in 3D genomics, today announced that an abstract reporting results of research into clinically actionable gene fusions was selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held April 8-13, 2022 in New Orleans.

Conducted in collaboration with Scripps MD Anderson Cancer Center, the research analyzed samples with known medically relevant gene fusions to understand the value of the Arima-HiC platform and short-read sequencing in identifying gene fusions from formalin-fixed, paraffin-embedded (FFPE) tumor biopsy samples. The researchers deployed a novel approach to identifying gene fusion using the Arima-HiC platform and found that it provided unbiased detection of both the known gene fusions and numerous other structural variants in each sample analyzed.

“Having access to accurate and highly sensitive information about gene fusions is critical to advancing our understanding of cancer biology and can be useful in identifying potential therapeutic options for individuals with cancer,” said Darren S. Sigal, M.D., program director of gastrointestinal oncology at Scripps MD Anderson Cancer Center and a Scripps Clinic physician. “Data from these types of analyses can facilitate future research into the relationship between disease mechanisms and clinical outcomes.”

The researchers looked at 12 FFPE adult tumor biopsies with known, clinically actionable gene fusions, including those involving common oncogenes such as ALK, NTRK3, ROS1, FGFR2, and SS18. The Arima Hi-C workflow successfully detected all known oncogenes, with 100 percent sensitivity, in addition to other structural variants.

“This research shows the utility of Hi-C technology in precision cancer research and demonstrates the capacity for 3D genomic approaches to provide both chromosome-scale and gene-level resolution for the detection of structural variants in FFPE tumor biopsy samples,” said Anthony Schmitt, Ph.D., Senior Vice President of Science at Arima Genomics. “Building on linear-based approaches that have driven our understanding of cancer genetics in the past, 3D genomics data enables new possibilities in the identification of genetic drivers of cancer and the development of novel therapeutics.”

About the Poster Presentation:

TItle: Sensitive and unbiased detection of clinically actionable gene fusions from FFPE tumor biopsies using the Arima HiC platform

Authors: David Jacob Hermel, M.D. (Scripps Health), Kristin Sikkink, Ph.D. (Arima Genomics), Derek Reid (Arima Genomics), Anthony Schmitt, Ph.D. (Arima Genomics), Darren S. Sigal, M.D. (Scripps MD Anderson Cancer Center and Scripps Clinic)

Location: American Association for Cancer Research (AACR) Annual Meeting, New Orleans Convention Center, Exhibit Halls D-H, Poster Section 4, to be displayed Sunday, April 10, 2022, 1:30 PM – 5:00 PM.

For more information, visit https://arimagenomics.com/events/aacr2022/

About Arima Genomics

Arima Genomics, Inc. is advancing life sciences research through the power of 3D genomics by providing unparalleled access to the sequence and structure of any genome. Arima Genomics offers the most advanced technologies for preserving the structural organization of the genome to drive discovery in genome biology and human health. To learn more, visit www.arimagenomics.com and connect with us on Twitter, LinkedIn, and YouTube.

Contacts –  Arima Genomics

Gwen Gordon

General inquiries
Pamela Bentley Mills, PhD